<DOC>
	<DOCNO>NCT00012155</DOCNO>
	<brief_summary>RATIONALE : Gene therapy may make body build immune response kill tumor cell . PURPOSE : Phase I trial study safety NV1020 patient colon cancer spread liver respond previous chemotherapy .</brief_summary>
	<brief_title>Gene Therapy Treating Patients With Colon Cancer That Has Spread Liver</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety maximum tolerate dose single intrahepatic NV1020 injection patient hepatic metastasis colon cancer fail first-line chemotherapy . - Determine tolerability drug patient . - Determine preliminarily anti-tumor activity drug patient . - Assess immunogenicity NV1020 patient . OUTLINE : This dose escalation study . Patients receive single intrahepatic arterial injection NV1020 10 minute aid hepatic arteriography . Cohorts 3 patient receive escalate dos NV1020 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 patient experience dose-limiting toxicity . Patients follow 1 , 2 , 3 month post injection . Patients may participate separate long term ( 1 year ) follow-up study continue assessment monitoring . PROJECTED ACCRUAL : A total 27 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon At least 3 metastatic hepatic lesion involve lobes No extrahepatic disease Failed firstline combination chemotherapy fluorouracil plus either leucovorin calcium irinotecan Herpes simplex virus type1 seropositive Candidate intrahepatic arterial infusion pump placement PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm^3 Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 9.0 g/dL No history blood clot disorder ( e.g. , hemophilia ) Hepatic : Transaminases great 3 time upper limit normal Bilirubin great 2.0 mg/dL No active hepatitis No history hepatic fibrosis , cirrhosis , hemochromatosis Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test All patient must use effective barrier contraception least 6 month study HIV negative No active herpes infection No active uncontrolled infection No prior weight loss 10 lb within past month No history alcohol substance abuse No concurrent unstable and/or severe medical psychological condition No history medical psychological condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy ( e.g. , interleukin2 , interleukin 12 , interferon ) No prior gene transfer therapy No prior therapy cytolytic virus type No concurrent immunotherapy 28 day study therapy No concurrent vaccine 28 day study therapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy 28 day study therapy Endocrine therapy : No concurrent systemic steroid 28 day study therapy Radiotherapy : No prior radiotherapy liver No concurrent radiotherapy 28 day study therapy Surgery : At least 2 week since prior surgery Other : At least 30 day since prior participation investigational study No concurrent antiviral agent active herpes simplex virus ( e.g. , acyclovir , valacyclovir , penciclovir , famciclovir , ganciclovir , foscarnet , cidofovir ) 28 day study therapy No concurrent immunosuppressive agent ( e.g. , cyclosporine ) 28 day study therapy No concurrent investigational anticancer agent 28 day study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>liver metastasis</keyword>
</DOC>